Quince Therapeutics (QNCX) has released an update.
Quince Therapeutics, Inc. has enhanced its board by appointing Rajiv Patni as a Class III director, effective February 15, 2024, with his term set to conclude at the 2025 Annual Meeting of Stockholders. Patni will receive the standard compensation for outside directors, including a $38,000 annual retainer and a stock option award for 54,000 shares, which vests over three years. Additionally, the company has provided Patni with an indemnification agreement to cover legal expenses related to his directorial role. Mr. Patni has no disclosed familial ties with other directors or significant transactions that could present a conflict of interest.
For further insights into QNCX stock, check out TipRanks’ Stock Analysis page.
